JP6290910B2 - ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 - Google Patents

ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 Download PDF

Info

Publication number
JP6290910B2
JP6290910B2 JP2015539867A JP2015539867A JP6290910B2 JP 6290910 B2 JP6290910 B2 JP 6290910B2 JP 2015539867 A JP2015539867 A JP 2015539867A JP 2015539867 A JP2015539867 A JP 2015539867A JP 6290910 B2 JP6290910 B2 JP 6290910B2
Authority
JP
Japan
Prior art keywords
usher
syndrome
compound
acid
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015539867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535256A5 (enExample
JP2015535256A (ja
Inventor
ブーリ，ローランド・ワーナー
エスミュ，ウィリアム・ラメシュチャンドラ・クリシュナ
ロック，クリストファー・ジェームズ
マラグ，カリネ・ファビエンヌ
オーエンズ，アンドリュー・ペイト
ハート，ウィリアム・エドワード
Original Assignee
アッシャー・サード・イニシアティブ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アッシャー・サード・イニシアティブ・インコーポレイテッド filed Critical アッシャー・サード・イニシアティブ・インコーポレイテッド
Publication of JP2015535256A publication Critical patent/JP2015535256A/ja
Publication of JP2015535256A5 publication Critical patent/JP2015535256A5/ja
Application granted granted Critical
Publication of JP6290910B2 publication Critical patent/JP6290910B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015539867A 2012-10-25 2013-10-25 ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法 Active JP6290910B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261718593P 2012-10-25 2012-10-25
US61/718,593 2012-10-25
US201361775376P 2013-03-08 2013-03-08
US61/775,376 2013-03-08
PCT/US2013/066938 WO2014066835A1 (en) 2012-10-25 2013-10-25 Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Publications (3)

Publication Number Publication Date
JP2015535256A JP2015535256A (ja) 2015-12-10
JP2015535256A5 JP2015535256A5 (enExample) 2016-12-08
JP6290910B2 true JP6290910B2 (ja) 2018-03-07

Family

ID=50545355

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015539867A Active JP6290910B2 (ja) 2012-10-25 2013-10-25 ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法

Country Status (10)

Country Link
EP (1) EP2912038B1 (enExample)
JP (1) JP6290910B2 (enExample)
AU (1) AU2013334138B2 (enExample)
CA (1) CA2889537C (enExample)
ES (1) ES2693166T3 (enExample)
IL (1) IL238287B (enExample)
PL (1) PL2912038T3 (enExample)
TR (1) TR201816028T4 (enExample)
WO (1) WO2014066835A1 (enExample)
ZA (1) ZA201502654B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2834049C (en) 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
AU2013334139B2 (en) * 2012-10-25 2017-08-03 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1435957B1 (en) * 2001-04-30 2009-06-17 Vertex Pharmaceuticals Incorporated Inhibitors of gsk-3 and crystal structures of gsk-3beta protein and protein complexes
CA2585934C (en) * 2004-10-29 2013-09-10 Abbott Laboratories Novel pyrazolopyridine urea kinase inhibitors
AR052559A1 (es) * 2005-01-21 2007-03-21 Astex Therapeutics Ltd Derivados de pirazol para inhibir cdk's y gsk's
JP2011503103A (ja) * 2007-11-07 2011-01-27 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド タンパク質輸送の調節方法
EP2361248B1 (en) * 2008-06-27 2018-09-19 Celgene CAR LLC Heteroaryl compounds and uses thereof
CA2834049C (en) * 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
AU2013334139B2 (en) * 2012-10-25 2017-08-03 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with Usher Syndrome

Also Published As

Publication number Publication date
IL238287A0 (en) 2015-06-30
IL238287B (en) 2018-07-31
CA2889537A1 (en) 2014-05-01
WO2014066835A1 (en) 2014-05-01
PL2912038T3 (pl) 2019-02-28
JP2015535256A (ja) 2015-12-10
EP2912038B1 (en) 2018-08-15
ES2693166T3 (es) 2018-12-07
HK1214263A1 (en) 2016-07-22
EP2912038A4 (en) 2016-04-20
EP2912038A1 (en) 2015-09-02
ZA201502654B (en) 2016-07-27
CA2889537C (en) 2017-12-12
TR201816028T4 (tr) 2018-11-21
AU2013334138B2 (en) 2017-07-27
AU2013334138A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
EP4034104B1 (en) Methods and compounds for restoring mutant p53 function
JP6291502B2 (ja) ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法
JP5902293B2 (ja) ピラゾロピリダジンおよび網膜変性疾患およびアッシャー症候群に伴う聴覚損失を治療するための方法
KR100722194B1 (ko) 피롤로[2,3디]피리미딘 조성물 및 이의 용도
AU2019289788A1 (en) Pyridinyl and pyrazinyl-(aza)indolsulfonamides
CN113993845A (zh) 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
WO2008025820A1 (en) Aminopyridine derivates as kinase inhibitors
US6914160B1 (en) Oxytocin inhibitors
CN1307178C (zh) 用作保胎催产素受体拮抗剂的新型三环吡啶基苯并氮杂䓬羧酰胺及其衍生物
SK15432003A3 (sk) 5-Substituované 2-arylpyridíny
JP6290910B2 (ja) ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法
US8765762B2 (en) Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
US20070232657A1 (en) Novel compounds
WO2008025526A1 (en) Indole derivatives, their manufacture and use as pharmaceutical agents
JP2002541145A (ja) アリールおよびヘテロアリール縮合アミノアルキル−イミダゾール誘導体：ブラジキニンｂ２受容体選択性モジュレータ
HK1214263B (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
JP2009504628A (ja) オキシトシン拮抗薬としての置換トリアゾール誘導体
HK40062458A (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
HK1195507A (en) Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180123

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180208

R150 Certificate of patent or registration of utility model

Ref document number: 6290910

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250